GSK Withdraws Autism Drug Application, Ending Trump-Backed Bid for FDA Approval

GSK has abruptly withdrawn its application to the U.S. Food and Drug Administration for an autism spectrum disorder drug, a candidate that had previously received high-profile backing from former President Donald Trump. The withdrawal comes just weeks after the pharmaceutical giant submitted the application, signaling a sudden reversal in its regulatory strategy for the treatment.

The drug, whose development was championed by Trump during his presidency as part of a push for new treatments, faced a critical juncture at the FDA. GSK's decision to pull the application halts the formal review process and leaves the future of this specific therapeutic approach in question. The company has not provided detailed reasons for the withdrawal in its brief statement, creating uncertainty around the data package or strategic considerations that led to the move.

This development represents a significant setback for a high-visibility project and removes a potential treatment option from the regulatory pipeline. It also underscores the complex and often unpredictable path for drugs targeting complex neurological conditions. The withdrawal will likely prompt scrutiny from investors and patient advocacy groups regarding GSK's neuroscience portfolio strategy and the viability of its research in this challenging therapeutic area.